Antiviral prodrugs and formulations thereof
View Patent ↗The present invention provides prodrugs and methods of use thereof.
1. A compound represented by formula:
or a pharmaceutically acceptable salt thereof, wherein R is a C4-C24 unsaturated or saturated aliphatic group, optionally substituted with at least one heteroatom.
2. The compound of claim 1 , wherein R is an alkyl chain of a fatty acid.
3. The compound of claim 1 , wherein said compound is selected from the group consisting of:
and pharmaceutically acceptable salts thereof.
4. A nanoparticle comprising at least one compound of claim 1 , or a pharmaceutically acceptable salt thereof, and at least one polymer or surfactant.
5. The nanoparticle of claim 4 , wherein said compound is crystalline.
6. The nanoparticle of claim 4 , wherein said polymer or surfactant is an amphiphilic block copolymer.
7. The nanoparticle of claim 6 , wherein said amphiphilic block copolymer comprises at least one block if poly(oxyethylene) and at least one block of poly(oxypropylene).
8. The nanoparticle of claim 6 , wherein the polymer or surfactant is P407.
9. The nanoparticle of claim 4 , wherein said nanoparticle further comprises a polymer or surfactant linked to at least one targeting ligand.
10. The nanoparticle of claim 4 , wherein the diameter of the nanoparticle is about 100 nm to 1 μm.
11. A composition comprising at least one nanoparticle of claim 4 and at least one pharmaceutically acceptable carrier.
12. A pharmaceutical composition comprising at least one compound of claim 1 , or a pharmaceutically acceptable salt thereof, and at least one pharmaceutically acceptable carrier.
13. A method for treating an HIV infection in a subject in need thereof, said method comprising administering to said subject an effective amount of a compound of claim 1 , or a pharmaceutically acceptable salt thereof.